Hyperinflammation in COVID-19 Obese Patients Treated With Tocilizumab: A Successful Case Series
The cytokine storm syndrome has been suggested as a mechanism in the pathophysiology of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2; COVID-19 [coronavirus disease 2019]) infection. Drugs such as tocilizumab, an interleukin-6 antagonist, have shown good results in other scenarios of h...
Main Authors: | Beatriz Amorim Beltrão RN, PhD, Rafael Cabral Teixeira MD, Diego Bastos Porto MD, MSc |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-07-01
|
Series: | Journal of Investigative Medicine High Impact Case Reports |
Online Access: | https://doi.org/10.1177/23247096211037442 |
Similar Items
-
Effect of pulsed corticosteroids and tocilizumab on hyperinflammation in COVID-19 patients with acute respiratory distress syndrome
by: Murat Aslan, et al.
Published: (2021-01-01) -
Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation
by: Nicola Potere, et al.
Published: (2020-11-01) -
Tocilizumab for refractory morphea in adults: A case series
by: Sarah Lonowski, MD, MBA, et al.
Published: (2022-12-01) -
Refractory neuro-Sweet disease successfully treated with tocilizumab and mycophenolate mofetil
by: Sungeun Hwang, et al.
Published: (2021-01-01) -
Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids
by: Francesca I. Calò Carducci, et al.
Published: (2020-11-01)